

Press release, May 29, 2009

New share issue in Biovitrum AB (publ)

In accordance with Biovitrum stock option program 2006:5 TO6 2006/2009, 180,756 new shares have been issued at the price SEK 59.00 per share, resulting in Biovitrum being provided funds of a total of SEK 10,664,604.00. The number of remaining stock options in the stock option program 2006:5 TO6 2006/2008 is 417,190.

After the share issue the outstanding number of shares in Biovitrum is 50,282,538.

For more information please contact:

Biovitrum

Göran Arvidson, CFO
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com

About Biovitrum

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit www.biovitrum.com.

Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on May 29, 2009 at 16:00 p.m. CET.